Youngsoo Kim - Eastwood Bio CEO Director
| EBM Stock | CAD 0.75 0.05 6.25% |
Insider
Youngsoo Kim is CEO Director of Eastwood Bio Medical Canada
| Address | 4871 Shell Road, Richmond, BC, Canada, V6X 3Z6 |
| Phone | 604 247 2100 |
| Web | https://www.eleotin.ca |
Eastwood Bio Management Efficiency
The company has return on total asset (ROA) of (0.6415) % which means that it has lost $0.6415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.4716) %, meaning that it generated substantial loss on money invested by shareholders. Eastwood Bio's management efficiency ratios could be used to measure how well Eastwood Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.85 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.22). At this time, Eastwood Bio's Non Current Assets Total are fairly stable compared to the past year. Asset Turnover is likely to climb to 1.21 in 2024, whereas Total Assets are likely to drop slightly above 418.2 K in 2024.Similar Executives
| Found 14 records | INSIDER Age | ||
| Mei Tian | biOasis Technologies | N/A | |
| Kim Elton | biOasis Technologies | N/A | |
| Justin MacDonald | Arch Biopartners | N/A | |
| B FTSE | biOasis Technologies | 64 | |
| Jamie Gowryluk | Medicure | N/A | |
| CPA BCom | Medicure | N/A | |
| Andrew CFA | Arch Biopartners | 58 | |
| Dave Jenkins | biOasis Technologies | N/A | |
| Doug MBA | biOasis Technologies | N/A | |
| Ron Hebert | Covalon Technologies | N/A | |
| Paul Beck | Arch Biopartners | N/A | |
| Simon Smith | Covalon Technologies | N/A | |
| Jason Gorel | Covalon Technologies | N/A | |
| Graeme Dick | biOasis Technologies | N/A | |
Management Performance
| Return On Equity | -7.47 | ||||
| Return On Asset | -0.64 |
Eastwood Bio Medical Leadership Team
Elected by the shareholders, the Eastwood Bio's board of directors comprises two types of representatives: Eastwood Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eastwood. The board's role is to monitor Eastwood Bio's management team and ensure that shareholders' interests are well served. Eastwood Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eastwood Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Youngsoo Kim, CEO Director | ||
| Yunji Esq, CFO and President |
Eastwood Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eastwood Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eastwood Stock Analysis
When running Eastwood Bio's price analysis, check to measure Eastwood Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eastwood Bio is operating at the current time. Most of Eastwood Bio's value examination focuses on studying past and present price action to predict the probability of Eastwood Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eastwood Bio's price. Additionally, you may evaluate how the addition of Eastwood Bio to your portfolios can decrease your overall portfolio volatility.